Copyright thehindubusinessline
Gland Pharma posted a 12 per cent increase in consolidated net profit at ₹184 crore in the second quarter ended September 30, 2025, compared to ₹163 crore in the corresponding quarter in the previous financial year. The total revenue of the Hyderabad-based company increased 6 per cent to ₹1,486 crore against ₹1,405 crore in the same period last year. “We expect stronger momentum in the second half, driven by new launches and Cenexi’s recovery. Our investments in global CDMO expansion, capacity enhancement in high-end modalities and complex injectables pipeline continue to strengthen our foundation and support sustainable growth and long-term value for all stakeholders,’’ said Srinivas Sadu, Executive Chairman, Gland Pharma, in a release on Monday. Shyamakant Giri, Chief Executive Officer, Gland Pharma, said: “For the quarter, Gland Pharma’s core business maintained its profitable growth trajectory with strong margin expansion. Encouragingly for consolidated business, we saw year-over-year improvement during Q2, with US growing 10 per cent and Europe 16 per cent supported by a 21 per cent top-line increase in Cenexi.’’ The company launched seven new molecules in the US during the quarter, including Daptomycin-RTU, Sumatriptan, new strength of Colistimethate. Six Abbreivated New Drug Applications were filed and five were approved in Q2 FY26, contributing to a cumulative total of 378 ANDA filings in the US. Published on November 3, 2025
